Impact To The Field – CFAR Network of Integrated Clinical Systems (CNICS)

The mission of CNICS is to provide access to the specimen and data repository to any investigator who submits an approved concept proposal. CNICS is a ‘peer-reviewed open access’ research platform available to investigators world-wide.

Upon submission of a concept study, the CNICS Administration will check for overlapping ideas or aims with an existing CNICS study to ensure each study has a unique data set without conflict. Should a new study be submitted that includes overlap, the CNICS Administration will work with researchers of both concepts to collaborate where research interests align.

CNICS has reviewed over 200 concept studies to date submitted by investigators at all levels, including graduate students, fellows, staff and faculty. These studies have resulted in over 350 peer reviewed manuscripts and over $125M in external funding awards to investigators working in CNICS, the majority of which are early career faculty and trainees.


Concept Number	Title of Concept Study	Investigator(s) Name	Institute
001	Impact of HAART and Metabolic Complications on Myocardial Infarction and Survival among HIV-infected Patients	Heidi Crane	University of Washington (UW)
002	Incidence and Risk Factors for Triple Class Antiretroviral Regimen (ARV) Exposure and Failure in the CNICS Cohort	Richard Haubrich	University of California San Diego (UCSD)
003	Biological and behavioral correlates of ART adherence and depression across diverse patients in the CNICS cohorts	Steven Safren	Fenway
004	The incidence and correlates of HIV superinfection before starting and after stopping antiretroviral therapy	Davey Smith	University of California San Diego (UCSD)
005	Viral Variation and the Development of Neutralizing Antibodies	Nancy L. Haigwood	University of Washington (UW)
006	gd-T cell Impairment and AIDS-associated Cancers	Richard Lopez	University of Alabama at Birmingham (UAB)
007	STI Burden and Behavioral Risks among HIV-infected Patients in Primary Care at CNICS collaborating sites	Kenneth Mayer	Fenway
008	Genetic variation and drug-drug interactions in tenofovir induced nephrotoxicity	Kathleen Giancomini	University of California San Francisco (UCSF)
009	Predictors of Severe Liver Enzyme Elevation and Immunologic Response to Initial HAART in Patients with HIV and Hepatitis Co-Infection	Chad Achenbach	Northwestern
010	Eligibility for Early Initiation of Highly Active Antiretroviral Therapy (HAART) to Decrease HIV Transmission/ Julie Dombrowski UW	Julie Dombrowski	University of Washington (UW)
011	Durability and Effectiveness of First-line ARV Regimens in treatment-naïve Patients Initiating Therapy in a Clinical Practice Setting	Michael Mugavero	University of Alabama at Birmingham (UAB)
012	Association of cellular immune function and phenotype with severe liver enzyme elevation (LEE) after Highly Active Antiretroviral Therapy (HAART) among HIV and viral hepatitis co-infected patients	Chad Achenbach	Northwestern
013	Long-term virologic outcomes of HIV-infected patients coinfected with hepatitis B on tenofovir-containing HAART	Nina Kim	University of Washington (UW)
014	Prevalence and associations of unprotected sex and substance use in the CNICS cohort	Matthew Mimiaga	Fenway
015	Dynamic Assessment of Virologic Response and Mortality Among HIV-infected Patients Initiating Antiretroviral Therapy	Michael Mugavero	University of Alabama at Birmingham (UAB)
016	An Analysis of Renal Function Before and After the Initiation of Highly Antiretroviral Therapy (HAART) to Examine Correlates of Renal Function Preservation and Decline	Robert Kalayjian	Case Western Reserve University (CWRU)
017	HIV Pathogenesis and Immunity in Viremic Non-Progressors	David Camerini	University of California Irvine (UC Irvine)
018	The Predictors of HIV+ smokers and investigation of smoking recognition and intervention by providers in two HIV ambulatory clinics	Karen Cropsey	University of Alabama at Birmingham (UAB)
019	Molecular Epidemiology of HIV Transmission and Transmitted Resistance in Women and Minorities in the CNICS Cohort	Jeannette Aldous	University of California San Diego (UCSD)
020	HIV infection in Sickle Cell Disease	Michael Lederman	Case Western Reserve University (CWRU)
021	Generalizing evidence from randomized clinical trials to target populations: the ACTG-320 trial	Steve Cole	University of North Carolina at Chapel Hill (UNC)
022	Comparison of plasma HIV RNA with CD4+ T cell count-based strategies for detection of first line treatment failure and initiation of regimen modification	Maya Peterson	University of California Berkeley
023	Measuring HIV transmission risk among HIV+ patients at CNICS sites	Joseph Schumacher	University of Alabama at Birmingham (UAB)
024	AIDS-defining and non-AIDS defining malignancies among the CFAR Network of Integrated Clinical Systems (CNICS)	Michael Saag	University of Alabama at Birmingham (UAB)
025	Effects of Hepatitis B co-infection on HIV Antiretroviral Therapy Response and Long-term Outcomes	Sarah Radke	University of North Carolina at Chapel Hill (UNC)
026	Heterogeneity in Cytokine Responses to HIV-1 Infection	James Tang	University of Alabama at Birmingham (UAB)
027	Methods to migrate from the 9-item Patient Health Questionnaire (PHQ-9) to computerized adaptive administration of the Patient Reported Outcomes Measurement Information System (PROMIS) depression measur	Heidi Crane	University of Washington (UW)
028	HIV Infection and Response to Initial Therapy for Type 2 Diabetes		University of Pennsylvania (UPENN)
029	Contribution of enzyme (protease) and substrate (gag) mutations to protease inhibitor resistance	David Looney	University of California San Diego (UCSD)
030	Epidemiology & Outcomes of HIV-2 in the United States	Geoffrey Gottlieb	University of Washington (UW)
031	Adherence to Clinical Care and Survival among HIV-infected Patients Initiating Antiretroviral Therapy	Michael Mugavero	University of Alabama at Birmingham (UAB)
032	HIV in the Elderly: Evaluating Indoleamine 2,3 dioxygenase as a marker for disease status	Stephanie Baer	Medical College of Georgia
033	HIV-associated Obstructive Pulmonary Disease Examinations (HOPE): Risk, Exacerbations, and Outcomes	Kristina Crothers	University of Washington (UW)
034	Prognosis of incidence and progression risk of AIDS-defining and non-AIDS-defining malignancies in HIV/AIDS patients	Julia Krauchanka	Duke University
035	Body morphology abnormalities and patient reported outcomes: depression, adherence, health-related quality of life, substance use, physical activity, and sexual risk behavior	Heidi Crane	University of Washington (UW)
036	Routine Laboratory Monitoring During Virologically Suppressive Combination Antiretroviral Therapy in the US	Babafemi Taiwo	Northwestern
037	Fine mapping of MHC susceptibility loci for AIDS-related non-Hodgkin lymphoma	Brahim Aissani	University of Alabama at Birmingham (UAB)
038	The Timing of Antiretroviral Initiation among ART Naïve HIV Infected patients in routine clinical practice	Elvin Geng	University of California San Francisco (UCSF)
039	Cross-walk between commonly used measures of anxiety in patients with HIV and the Patient Reported Outcomes Measurement Information System (PROMIS) anxiety measure	Heidi Crane	University of Washington (UW)
040	Determinants of Transmitted Drug Resistance (TDR) and Impact of “Test and Treat” Strategy on Transmission of Drug Resistance Among HIV-1 Infected Treatment-Naïve Patients: Influence of High Risk Behaviors as Determined by Patient Based Metrics (PBM) on TDR Prevalence and Modeled Probability of Transmission	Vi Bowman	University of California San Diego
041	Systematic Characterization of High-Risk HPV Infection in Head and Neck Carcinoma in HIV+ Individuals	Margaret Brandwein-Gensler	University of Alabama at Birmingham
042	Durability of initial compared to subsequent HAART regimens	Eric Sahloff	University of Toledo
043	Comparing Results from Two Methods for Estimating the Optimal CD4 Threshold for Initiating Antiretroviral Therapy	Bryan Shephard	Vanderbilt University
044	Biological Determinants of Long-term Immune Reconstitution following Combination Antiretroviral Therapy (cART)	Sharon Lewin	Monash University Australia
045	BMI, Depression, and HIV Self-Care Behaviors among MSM	Aaron Blashill	Fenway
046	Impact of presenting clinical features and subsequent treatment on outcomes after non-CNS HIV-associated lymphoma in the CNICS cohort	Satish Gopal	University of North Carolina at Chapel Hill (UNC)
047	Time related factors of platelet count reduction in human immunodeficiency virus/HIV and Hepatitis C/HCV co-infected antiretroviral therapy/ARV Naiive patients	Chris Delaney	University of Florida
048	Structural models for exposure effects in HIV progression cohorts	Steve Cole	University of North Carolina at Chapel Hill (UNC)
049	Effects of Combination Antiretroviral Therapy on Risk of Non-AIDS- defining Cancers/ STUDY CLOSED	Elizabeth Yanik	University of North Carolina at Chapel Hill (UNC)
050	The Causal Effect of Antidepressant Treatment on HIV Outcomes in the CNICS Multi-Site Observational Clinical Cohort: An Application of Marginal Structural Models	Brian Pence	Duke University
051	Risk Factors and microRNA Profiles of HIV Associated Lung Cancer	Kristina Crothers and Lynn Schnapp	University of Washington (UW)
052	Molecular epidemiology of HIV transmission networks between Rhode Island and Massachusetts	Phillip Chan	Brown University
053	Incidence and treatment of prostate cancer in HIV-infected men: do racial disparities exist?	Ramona Bhatia	Northwestern
054	Impact of Transitioning from HIV Clinical Trials to Routine Medical Care on Virologic and Immunologic Outcomes	Baligh R. Yehia	University of Pennsylvania (UPENN)
055	Current practice of screening for incident HCV infection among HIV-infected individuals	Benjamin Linas	Boston Medical Center
056	Evaluating the Relationship between HIV Transmission Networks in the San Diego-Tijuana Cross-Border HIV Epidemic and the Rest of the United States and the Difference between Geographically Localized and Geographically Diverse Transmission Networks	Sanjay Mehta	University of California San Diego (UCSD)
057	The Natural History of Malignancies Developing Among HIV Positive Individuals on Stable Antiretroviral Therapy	Anna Coghill	University of Washington (UW)
058	Endothelial Dysfunction, Antiretroviral Therapy, and Non-AIDS Defining Events in the CNICS Cohort	Susan Graham	University of Washington (UW)
059	When to switch cART: A comparison of switching strategies using observational data	Lauren Cain	Harvard University
060	Effects of Hepatitis C Co-infection on HIV Disease Progression and Long term Outcomes	Jennifer Ling	University of Washington (UW)
061	Frailty in HIV-infected older adults	Charles Kamen and Supriya Mohile	University of Rochester
062	STI Screening and Determinants of Infection Among HIV-Infected Patients in Primary Care	Kenneth Mayer	Fenway
063	Diagnosis and Treatment of Depression in HIV/AIDS Primary Care: A Comparative Analysis of Latino and Non-Latino White Patients	Oscar Beltran	University of Texas at El Paso (UTEP)
064	Behavioral predictors of outcomes in HIV infected adolescents	Brian Zanoni	Massachusetts General Hospital, Fenway Community Health
065	Optimal timing for starting cART in antiretroviral-naïve HIV-1–infected patients presenting with cryptococcal meningitis	Jonathan Sterne	University of Bristol
066	Plasma cell neoplasms in HIV infected people: a multi center case series/ STUDY CLOSED	Eric Engels	National Cancer Institute
067	Molecular profiling of HIV-associated lymphoma occurring before and during antiretroviral therapy	Satish Gopal	University of North Carolina at Chapel Hill (UNC)
068	Alcohol Research Consortium in HIV – Epidemiological Research Arm (ARCH-ERA) U01AA020793	Heidi Crane	University of Washington (UW)
068b	Alcohol Research Consortium in HIV: COVID Supplement	Heidi Crane	University of Washington (UW)
069	Comparative effectiveness of SSRIs and SGAs among patients aging with HIV	Heidi Crane	University of Washington (UW)
070	OMCICH: Optimal Multidisciplinary Care in the Clinical HIV Setting	Michael Horberg	Mid-Atlantic Kaiser Permanente Group
071	Factors that influence the response to Hepatitis A vaccine among HIV-infected individuals	Heidi Crane	University of Washington (UW)
072	Statins in HIV: Immune Reconstitution, Comorbid Events, and Survival	Dan Drozd	University of Washington (UW)
073	Epidemiology of Cerebrovascular Disease in CNICS	David Tirschwell	University of Washington (UW)
074	Race-specific association between CCR5 -2459G>A genotype and virologic response to HAART in the CNICS cohort/ STUDY CLOSED	Rajeev Mehlotra	Case Western Reserve University (CWRU)
075	Modeling the dynamic association of BMI and mortality in HIV positive adults/ STUDY CLOSED	Jianghua He	University of Massachusetts (UMASS)
076	Relationship of virologic suppression and control of cardiometabolic comorbidities in HIV-infected patients on antiretroviral therapy	Greer Burkholder	University of Alabama at Birmingham (UAB)
077	Incidence and treatment of anal cancer in HIV-infected individuals: do racial/ethnic disparities exist?	Candice McNeil	Stanford University
078	Hepatitis C treatment uptake and predictors of HCV therapy among HIV-infected individuals in the era of direct-acting antiviral agents	Ed Cachay	University of California San Diego (UCSD)
079	Sero-incidence of Herpes Simplex Virus Types 1 and 2 in HIV-infected persons receiving HIV-care	Nicholas Van Wagoner	University of Alabama at Birmingham (UAB)
080	Circulating MicroRNAs in HIV-infected Patients with and without Coronary Artery Disease	Venkata Narla and Priscilla Hsue	University of California San Francisco
081	Understanding Patient Populations Receiving Antiretroviral Therapy: Observational Channeling Bias Study	Michael Saag, Steve Cole and Andy Westfall	University of Alabama at Birmingham (UAB) & University of North Carolina at Chapel Hill (UNC)
082	Assessment of Markers of Microbial Translocation, Gut Mucosal Integrity, and Inflammation in HIV-infected Patients with Delayed Vs. Normal Immune Recovery on Suppressive Antiretroviral Therapy	Gregory Huhn, Peter Hunt and Bellur Prabhakar	Chicago Cook County Hospital
083	Effectiveness of Antiretroviral Therapy (ART) with Upfront Chemotherapy versus ART Alone in HIV-Infected Patients with Kaposi’s Sarcoma Who Do Not Have Urgent Indications for Chemotherapy/ STUDY CLOSED	Jackie Wang	University of California San Francisco (UCSF)
084	Selection bias due to restriction in cohort studies	Chanelle Howe	Brown University
085	Antiretroviral switches in HIV/HCV co-infected patients: Initiating direct acting antiviral therapies for Hepatitis C Infection	Julius Wilder and Susanna Naggie	Duke University
086	HIV-related Health Disparities in Latinos Living with HIV in the United States	John Sauceda	University of California San Francisco
087	When to monitor: A comparison of immunologic and virologic monitoring strategies using observational data	Ellen Caniglia	Harvard University
088	Differential Virologic and Resistance Outcomes when using Efavirenz-based Single Tablet Regimens versus Multiple Tablet Regimens in HIV Treatment	Michael Saag and Andy Westfall	University of Alabama at Birmingham (UAB)
089	Calcium antagonist and CVD risk among hypertensive HIV+ patients	Sadeep Shrestha	University of Alabama at Birmingham (UAB)
090	Identify and Manage Promptly Incident Hepatitis C: Testing to Treatment in HIV (IMPACT-C)/ STUDY CLOSED	Benjamin Linas and Lynn Taylor	Boston Medical Center
091	Preventive fractions of Kaposi sarcoma and non-Hodgkin lymphoma in the modern ART era	Elizabeth Yanik	National Cancer Instittute
092	Application of the Updated ACC/AHA Atherosclerotic CVD Risk Assessment Tool and Prevention Guidelines Among HIV-Infected Individuals: CFAR Network of Integrated Clinical Systems (CNICS)	Matthew Feinstein	Northwestern
093	Analysis of CNICS data to inform design of interventions to enhance HIV care among substance abusers	Bryan Hartzler	University of Washington (UW)
094	Population interventions on smoking in the CNICS/ Bryan Hartzler UW	Bryan Hartzler	University of Washington (UW)
095	Factors Associated with HAART Medication Adherence among Older Adults Living with HIV in the U.S.	Brian Witt	University of North Carolina at Chapel Hill (UNC)
096	The Affordable Care Act, Socioeconomic Context, Spatial Mapping, and Outcomes Among People Living With HIV	Aadaora Adimora	University of North Carolina at Chapel Hill (UNC)
097	Pathways contributing to racial and economic disparities among HIV clinic cohort patients/ STUDY CLOSED	Chanelle Brown	Brown University
098	Genomic approaches to cardiometabolic risk and treatment in HIV	Inga Peter	Mount Sinai
099	Investigating the relationship between chronic pain and HIV outcomes	Jessie Merlin	University of Alabama at Birmingham (UAB)
100	Cardiovascular, pulmonary, and hematological disease in HIV: Prevention and Treatment	Heidi Crane	University of Washington (UW)
101	Statin use among HIV-infected patients	Greer Burkholder	University of Alabama at Birmingham (UAB)
102	Comparative Effectiveness of Single-Action verses Multi-Action Antidepressants on Depression, Treatment Adherence and HIV Clinical Outcomes among People Living with HIV/AIDS and Depression	Jon Mills	University of North Carolina at Chapel Hill (UNC)
103	Development and Validation of a Multidimensional Index of Engagement in HIV Care	Kristian Christopoulos and Mallory Johnson	University of California San Francisco (UCSF)
104	Calibration of a 1-Year Virologic Prediction Rule for Race/Ethnicity and Gender.	Gregory Robbins	Mass Gen/ Harvard University
105	The HIV Care Continuum: CD4 and Viral Load Measures as Proxies for Routine HIV Care Visits	Kimberly Powers	University of North Carolina at Chapel Hill (UNC)
106	Diminishing “Clinic Viral Load” in CNICS clinics in the U.S.: Socio-demographic and Therapeutic Correlations with Adherence	Jane Simoni	University of Washington (UW)
107	The CD4/CD8 ratio as a predictor of adverse outcomes in HIV-infected subjects under suppressive antiretroviral therapy and elite controllers	Sergio Serrano-Villar	University Hospital Ramón y Cajal- Madrid, Spain
108	Modeling Depression Treatment Strategies for Human Immunodeficiency Virus (HIV) Positive Patients	Rongbing Xie	University of Alabama at Birmingham (UAB)
109	Physical activity patterns and metabolic disease outcomes in people living with HIV	Amanda Willig	University of Alabama at Birmingham (UAB)
110	Projected Burden of Chronic Disease within the PLWH Population	Julia Hood	University of Washington (UW)
111	Impact of low-level HIV viremia on cancer risk	Jennifer Lee	University of North Carolina at Chapel Hill (UNC)
112	A statistical framework for integrated analysis of the HIV care cascade using CNICS data	Hanna Lee	Brown University
113	What to start: co-formulated versus individual tablets regimens in high-income countries	Sarah Lodi	Harvard University
114	Self-management and quality of life in persons with HIV and diabetes, a comparison study.	Julie Zuniga	University of Texas Austin
115	Lipidomic Profiling in HIV patients newly initiating antiretroviral treatment	Ryan Irvin	University of Alabama at Birmingham (UAB)
116	Identification of Novel Metabolic Biomarkers for Predicting Cardiovascular Events in Persons Living with HIV	Svati Shah	Duke University
117	Supplement to Approved CP 103: Development and Validation of a Multidimensional Index of Engagement in HIV Care	Kristina Christopoulos and Mallory Johnson	University of California San Francisco (UCSF)
118	Efavirenz and the risk of suicidality	Angela Bengston	University of North Carolina at Chapel Hill (UNC)
119	Age and Risk of HAART-Associated Nephrotoxicity: a Retrospective Cohort Study	Jessie Torgersen	Hospital of the University of Pennsylvania
120	Pathways contributing to racial/ethnic disparities among HIV clinic cohort patients	Chanelle Howe	Brown University
121	Combined when to start analyses of the START trial, HIV-CAUSAL and CNICS	Steve Cole	University of North Carolina at Chapel Hill (UNC)
122	At-Risk Alcohol Use and the Completion of Patient Reported Outcomes	Jacquelin Rudolph	University of North Carolina at Chapel Hill (UNC)
123	Examining causes of death among patients with HIV in the United States: methodologic tools and applications	Jess Edwards	University of North Carolina at Chapel Hill (UNC)
124	Health Outcomes Among Transgender Patients in HIV Care: Findings from the CNICS Cohort	Sari Reisner	Fenway
125	Durability of Contemporary Antiretroviral Regimens in Treatment Naïve Persons living with HIV	Ellen Eaton	University of Alabama at Birmingham (UAB)
126	Phylogeographic approach to determine the dynamics of HIV in circulating cellular reservoirs during ART failure and after re-suppression.	Antoine Chaillon	University of California San Diego (UCSD)
127	Kidney Failure Risk Projection for the HIV-infected Living Kidney Donor Candidate	Jayme Locke	University of Alabama at Birmingham (UAB)
128	The Syndemics of Aging with HIV	Maile Karris	University of California San Diego (UCSD)
129	Hemoglobin as a criterion to switch antiretroviral therapy in HIV-positive individuals	Lauren Cain	Harvard University
130	Comparative effectiveness of integrase-inhibitor-based regimens versus NNTRI- and boosted-PI-based regimens.	Steve Cole	University of North Carolina at Chapel Hill (UNC)
131	Patient-reported sexual risk behavior and viral suppression over time	Julia Raifman	John Hopkins Bloomberg School of Public Health
132	Comparing Duraility, Treatment Failure and Emergence of Resistance on Integrase Stand Transfer Inhibitor Treatment Regimens Among Treatment-Naïve and Treatment-Experienced Patients with HIV (UAB Protocol # X151228001)	Heidi Crane	University of Washington (UW)
133	A Feasibility and Pilot Study of Clinical Outcomes among Transgender Women Living with HIV	Tonia Poteat	John Hopkins Bloomberg School of Public Health
134	The impact of substance use on health outcomes over time among persons living with HIV	W. Scott Comulada	University of California Los Angeles (UCLA)
135	The Joint Effects and Plausible Interventions for ART and Statin Use on Mortality	Jonathan Post	University of North Carolina at Chapel Hill (UNC)
136	Multi-level Social and Behavioral Determinants of Health and Missed HIV Healthcare Provider Visits	April Pettit	Vanderbilt University
137	Physical Activity and Symptom Distress in HIV+ Adults in the CNICS Database	Allison Webel	Case Western Reserve University
138	Statin use to prevent progression of liver disease among HIV infected individuals	Bryan Lau	John Hopkins University
139	Real World Effectiveness of Direct-Acting Antiviral Agents for Hepatitis C Infection Among HIV/HCV-Coinfected Patients	Nina Kim	University of Washington (UW)
140	Cigarette Smoking and HIV Treatment Outcomes Among MSM in Primary Care	Conall O'Cleirigh	Harvard University
141	Epidemiology of Heavily Treatment-Experienced (HTE) HIV Patients in the US	Michael Saag and Ellen Eaton	University of Alabama at Birmingham (UAB)
142	Development and Validation of Risk Prediction Model for End Stage Liver Disease and Hepatocellular Carcinoma in Persons living with HIV	Nina Kim	University of Washington (UW)
143	Evaluation of the efficacy, mechanism, and cost-effectiveness of Skills TO Manage Pain (STOMP), a novel group and peer-based behavioral intervention for chronic pain tailored to people living with HIV	Jessie Merlin	University of Alabama at Birmingham (UAB)
144	Rates and Predictors of Bacterial STI in Women with HIV	Jodie Dionne-Odom	University of Alabama at Birmingham (UAB)
145	Diabetes as a risk factor for tuberculosis in HIV positive individuals in the United States	Kristina Bajema	University of Washington (UW)
146	A personalized approach to mental health in HIV	Todd Fojo	John Hopkins University
147	Epidemiology of HIV-related atrial fibrillation and associations with substance abuse	Susan Heckbert	University of Washington (UW)
148	Estimating the potential pool of HIV-infected deceased organ donors in the United States	Jayme Locke	University of Alabama at Birmingham (UAB)
149	Primary Infection Resource Consortium (PIRC)	Susan Little	University of California San Diego (UCSD)
150	Patterns and Perceptions of e-Cigarettes and Vaporized Nicotine Among People Living with HIV	Rob Fredericksen	University of Washington (UW)
151	Longitudinal HIV Care Trajectories and HIV Transmission Risk from the Time of HIV Care Entry in the CNICS	Kimberly Powers	University of North Carolina at Chapel Hill (UNC)
152	Condom-less sex behavior and health outcomes among HIV-infected patients in the PrEP era	Rob Fredericksen	University of Washington (UW)
153	Patient Usability and Acceptability of Electronic Patient-Reported Outcome Measures for Use in HIV Care	Rob Fredericksen	University of Washington (UW)
154	Plasma IL-6 signaling biomarkers and cardiovascular disease in the CNICS cohort	Lee Sulggi	University of California San Francisco (UCSF)
155	HIV/HCV Coinfection and Incidence of Extrahepatic Cancers	Julia Marcus	Harvard University
156	Predictive Analytics for Retention in HIV Care	Jessica Ridgway	University of Chicago
157	Understanding the effect of physical activity and dietary intake on the longitudinal symptom experience of HIV+ adults in the CNICS cohort	Allison Webel and Amanda Willig	Case Western Reserve University (CWRU) & University of Alabama at Birmingham (UAB)
157a	Examining HIV-related Symptom Moderation of the Executive Function/Self-Management Process	Nathaniel Schreiner	Case Western Reserve University (CWRU)
158	Preparing for Long-Acting Injectable ART: Patient and Provider Perceptions, Preferences, and Shared Decision-Making	David Wohl	University of North Carolina at Chapel Hill (UNC)
159	Health Outcomes among Patients in HIV Care Reporting Intimate Partner Violence	Rob Fredericksen	University of Washington (UW)
160	Impact and Correlates of Sub-Optimal Social Support Among Patients in HIV Care	Rob Fredericksen	University of Washington (UW)
161	Health Disparities and Social Determinants for HIV-Associated Neurocognitive Disorders and its Risk Factors	Pariya Fazeli Wheeler	University of Alabama at Birmingham (UAB)
162	Viral suppression and sexual risk among people living with HIV: potential impact of risk compensation on HIV transmission	Heather Pines	University of California San Diego (UCSD)
163	Improving Kidney Health for African Americans with HIV through Optimal Antiretroviral Therapy Selection	Ellen Eaton	University of Alabama at Birmingham (UAB)
164	Role of medication assisted treatment on HIV treatment outcomes among opioid and stimulant users	Javier Cepeda	University of California San Diego (UCSD)
165	Effectiveness of second-line antiretroviral therapy	Thibaut Davy-Mende	University of North Carolina at Chapel Hill (UNC)
166	Genes, substance use, and HIV outcomes in people living with HIV across the US	Heidi Crane	University of Washington (UW)
167	Interventions to prevent cardiovascular disease among people living with HIV	Alexander Breskin	University of North Carolina at Chapel Hill (UNC)
168	Characterization of Symptom Clusters Among People Living With HIV Disease	Natalie Wilson	University of California San Francisco (UCSF)
169	Effectiveness of a smoking cessation algorithm integrated into HIV primary care.	Karen Cropsey	University of Alabama at Birmingham (UAB)
170	Determinants and Outcomes of Nicotine Metabolism in HIV	Robert Gross	University of Pennsylvania (UPENN)
171	Marijuana policy change impact on patterns of marijuana and other harmful substance use among people living with HIV: a mixed methods evaluation	Andrew Hahn	University of Washington (UW)
172	Prevalence and Risk Factors for Hepatitis Delta Infection Among a Cohort of HIV/Hepatitis B-Coinfected Patients in the United States	Vincent Lo Re	University of Pennsylvania (UPENN)
173	Optimizing the Implementation of the U=U Strategy for HIV Prevention in Clinic Settings	Curt Beckwith	Brown University
174	Substance use and risk of stroke among people living with HIV	Thomas Martin	University of California San Diego (UCSD)
175	Host genetics and risk of anal cancer among patients living with HIV	Helen Stankiewicz Karit	University of Washington (UW)
176	Genetic predictors of adiposity-related traits including body mass index, lipoatrophy, lipohypertrophy and ART treatment-induced obesity among people living with HIV	Sara Lindstroem	University of Washington (UW)
177	Gender Identity and Participation in Biomedical Research	April Pettit	Vanderbilt University
178	Differences in substance use patterns among people living with HIV by geographic region	Heidi Crane	University of Washington (UW)
179	Mental health, alcohol, and other substance use disorders Prevalence, co-occurrence and durability of symptoms; pharmacologic treatment initiation and retention; and impact of treatment on retention in HIV care and viral suppression	Catherine Lesko	John Hopkins University
180	Factors associated with Initiating Care for Vulnerable HIV-Infected Individuals with Substance Use	Canada Parrish	University of Washington (UW)
181	Evaluating the impact of food insecurity on diabetes risk and treatment outcomes among adults with HIV+ in the PROSPER-HIV study	Allison Webel and Amanda Willig	Case Western Reserve University (CWRU) & University of Alabama at Birmingham (UAB)
182	Machine learning to identify persons at high-risk of disengaging from HIV care in the United States	Sahar Saeed	Washington University in St. Louis
183	Impact of COVID-19 among people living with HIV in the CNICS cohort: overall and symptomatic incidence, predictors of disease, adverse clinical outcomes, and mortality	Ed Cachay, Lalo and Adrienne Shapiro	University of Washington (UW)
184	Impact of FUT2 Genetic Variability on HIV-associated Inflammation.	Mohamed Abdel-Mohsen	Wistar Institute
185	Quality of life validation studies in CNICS	Heidi Crane	University of Washington (UW)
186	Impact of childhood abuse on health outcomes among patients living with HIV	Rob Fredericksen	University of Washington (UW)
187	Burden of Morbidity and Premature Mortality in patients with HIV-associated Malignancies	Guarav Goyal	University of Alabama at Birmingham (UAB)
188	Antiretroviral Utilization in the Current Treatment Era (2018-2020)	Jimmy Ma	University of Washington (UW)
189	Patient Perceptions of the Impact of the SARS-CoV-2 pandemic: Impact on patient reported outcomes and HIV-related outcome disparities	Mallory Johnson	University of California San Francisco (UCSF)
190	Trauma and adherence: A lifecourse approach to understanding HIV in older adults	Paul Nash	University of Southern California
191	A cross sectional analysis of psychological stress, physical activity, and viral suppression as predictors of Cardiovascular Disease risk in older persons with HIV	Crista Irwin	Emory University
192	Mentoring Patient-Oriented Research on Advances to Optimize Engagement in HIV Care	Katerina Christopoulos	University of California San Francisco (UCSF)
193	Relationship between body fat and functional status among adults aging with HIV	Vitor Oliveira	Case Western Reserve University
194	Deep Phenotyping of HIV-Related Heart Failure	Matthew Feinstein	Northwestern
195	Internalized HIV Stigma and Viral Suppression: Examining the Mediating and Moderating Roles of Social Support, Substance Use, and Depressive Symptoms	Timothy Crawford	Wright State University Boonshoft School of Medicine
196	Psychosocial Effects of HIV Nondisclosure Laws Among People Living with HIV	Steve Safren	University of Miami
198	Determination of the Impact of Abnormal Glucose Levels on Progression to Frailty Among People Living with HIV	Andrew Hahn	University of Washington (UW)
199	Social Determinants of Health Disparities and Multiple Co-morbidities among Men and Women Living with HIV	Jenni Wise	University of Alabama at Birmingham (UAB)
200	Examining influences on physical activity behaviors and quality of life among adults living with HIV	Sable Watson	University of North Carolina at Chapel Hill (UNC)
201	Host Genetic Predictors of Vascular Complications: A CNICS Mendelian Randomization Study	Sulggi Lee	University of Chicago
203	Impact of ongoing COVID-19 pandemic on people with HIV in the US	Adrienne Shapiro	University of Washington (UW)
204	Cardiometabolic Disease Among Frailty Clusters in Adults Aging with HIV	Raymond Jones	University of Alabama at Birmingham (UAB)
205	Understanding Racial and the Social Determinants of Disparities in Depression and Non-Communicable Disease Outcomes in Adults Living with HIV	Aima Ahonkhai	Vanderbilt University
206	Effect of Internalized HIV Stigma on Cardiovascular Disease Risk in Women Living with HIV	Jess Sherman	Ohio State University
207	Impact of depression and HIV symptoms on glycemic outcomes (A1c, BG) among patients living with HIV and type 2 diabetes.	Veronica Brady	University of Texas Health Science Center at Houston
208	Role of integrase strand transfer based regimens in people with HIV and hypertension	Mohammed Siddiqui	University of Alabama at Birmingham (UAB)
209	Internalized HIV Stigma, Age and Gender related outcomes among people with HIV (HIV StAGe Outcomes)	Lydia Drumright	University of Washington (UW)
210	Epidemiology of monkeypox among people with HIV in the CNICS cohort: incidence, clinical outcomes, access to treatment, and predictors of disease acquisition and severity	Michalina Montano	University of Washington (UW)
211	Identifying genetic contributors for cardiovascular disease with people with HIV-infection	Nicole Armstrong	University of Alabama at Birmingham (UAB)
212	Aging, Depressive Symptoms, Antidepressant Effectiveness, and Incidence of Stroke among People with HIV	Jimmy Ma	University of Washington (UW)
213	Alcohol Research Consortium in HIV – Epidemiological Research Arm from P01 AA029544	Heidi Crane	University of Washington (UW)
214	Re-demonstrating the clinical relevance of retention in care: A longitudinal multisite analysis of two cohorts	Emma Kay	Birmingham AIDS Outreach (BAO)
215	Characterization and Clustering of Symptoms in People with HIV	Tru Cao	University of Texas Health Science Center at Houston
217	Human monkeypox (MPX) vaccination among men who have sex with men (MSM) and/or transgender women in the CNICS cohort: vaccine uptake and hesitancy beliefs	Rob Fredericksen	University of Washington (UW)
219	Renewal application: Impact of Physical Activity Routines and Dietary Intake on the Longitudinal Symptom Experience of the people living with HIV (PROSPER-HIV 2)	Allison Webel and Mandy Willig	University of Alabama at Birmingham (UAB)
220	Evaluating Risk Factors and Prevalence of Hepatitis C Viremia among People with HIV in the Direct Acting Antiviral Era	Jimmy Ma	University of Washington (UW)
222	Evaluating the impact of genital STI diagnosis on incidence of HCV infection in PWH	Yotam Arens	University of Pennsylvania (UPENN)
224	Eicosanoids as Novel Inflammatory Mediators of CVD in Men and Women with HIV	Claudia Martinez	Medical University of South Carolina
225	Innovative Computational Tools and Best Practice Recommendations for Analyzing HIV-related Count Outcomes	David Huh	University of Washington (UW)
227	Elucidating Genetic Risk Factors for AKI and AKI-related Outcomes among People with HIV	Molly Fisher	Albert Einstein College of Medicine, Montefiore Medical Center
228	Addressing Barriers to the Comprehensive Use of Statins in people with HIV: the ABACUS-HIV study	Thibaut Davy-Mendez	University of North Carolina at Chapel Hill (UNC)
230	Associations Between Chronic Kidney Disease (CKD) and Substance Use, Hypertension, Insomnia, and Diabetes Among PWH	Chris Delaney	University of Washington (UW)
232	Frailty and frailty transitions in aging persons with HIV: are they associated with serum miRNA profiles?	Lee D Chaves	University of Kansas Medical Center
233	Syndemic Trajectories among Gay, Bisexual, and Other Men Who Have Sex with Men living with HIV in the U.S.	Pablo Valente	University of Connecticut (UConn)